Eculizumab for the treatment of preeclampsia/HELLP syndrome

Richard Burwick, B. B. Feinberg

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Severe preeclampsia with hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome is a leading cause of maternal and neonatal morbidity and mortality worldwide. Occurrence at an extremely premature gestational age is most challenging as there are dichotomous imperatives: delivery as definitive therapy for maternal health vs. prolongation of pregnancy to avoid prematurity and associated morbidities. We describe a patient presenting with severe preeclampsia/HELLP syndrome at 26 weeks gestation that was treated with Eculizumab, a targeted inhibitor of complement protein C5, which resulted in marked clinical improvement and complete normalization of lab parameters. Pregnancy was prolonged 17 days, likely resulting in a reduction of neonatal morbidity with its associated short and long-term health care costs. Successful use of Eculizumab in this case suggests that complement inhibition may be an effective treatment strategy for severe preeclampsia/HELLP syndrome.

Original languageEnglish (US)
Pages (from-to)201-203
Number of pages3
JournalPlacenta
Volume34
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Hemolysis
Pre-Eclampsia
Blood Platelets
Morbidity
Liver
Enzymes
Complement C5
Prolonged Pregnancy
Pregnancy
Infant Mortality
Long-Term Care
Health Care Costs
Gestational Age
Complement System Proteins
Therapeutics
Mothers
eculizumab

Keywords

  • C5
  • Complement
  • Eculizumab
  • HELLP syndrome
  • Preeclampsia
  • Pregnancy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine
  • Developmental Biology

Cite this

Eculizumab for the treatment of preeclampsia/HELLP syndrome. / Burwick, Richard; Feinberg, B. B.

In: Placenta, Vol. 34, No. 2, 02.2013, p. 201-203.

Research output: Contribution to journalArticle

Burwick, Richard ; Feinberg, B. B. / Eculizumab for the treatment of preeclampsia/HELLP syndrome. In: Placenta. 2013 ; Vol. 34, No. 2. pp. 201-203.
@article{20f387f41b6143b0b81961bbda58f51d,
title = "Eculizumab for the treatment of preeclampsia/HELLP syndrome",
abstract = "Severe preeclampsia with hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome is a leading cause of maternal and neonatal morbidity and mortality worldwide. Occurrence at an extremely premature gestational age is most challenging as there are dichotomous imperatives: delivery as definitive therapy for maternal health vs. prolongation of pregnancy to avoid prematurity and associated morbidities. We describe a patient presenting with severe preeclampsia/HELLP syndrome at 26 weeks gestation that was treated with Eculizumab, a targeted inhibitor of complement protein C5, which resulted in marked clinical improvement and complete normalization of lab parameters. Pregnancy was prolonged 17 days, likely resulting in a reduction of neonatal morbidity with its associated short and long-term health care costs. Successful use of Eculizumab in this case suggests that complement inhibition may be an effective treatment strategy for severe preeclampsia/HELLP syndrome.",
keywords = "C5, Complement, Eculizumab, HELLP syndrome, Preeclampsia, Pregnancy",
author = "Richard Burwick and Feinberg, {B. B.}",
year = "2013",
month = "2",
doi = "10.1016/j.placenta.2012.11.014",
language = "English (US)",
volume = "34",
pages = "201--203",
journal = "Placenta",
issn = "0143-4004",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Eculizumab for the treatment of preeclampsia/HELLP syndrome

AU - Burwick, Richard

AU - Feinberg, B. B.

PY - 2013/2

Y1 - 2013/2

N2 - Severe preeclampsia with hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome is a leading cause of maternal and neonatal morbidity and mortality worldwide. Occurrence at an extremely premature gestational age is most challenging as there are dichotomous imperatives: delivery as definitive therapy for maternal health vs. prolongation of pregnancy to avoid prematurity and associated morbidities. We describe a patient presenting with severe preeclampsia/HELLP syndrome at 26 weeks gestation that was treated with Eculizumab, a targeted inhibitor of complement protein C5, which resulted in marked clinical improvement and complete normalization of lab parameters. Pregnancy was prolonged 17 days, likely resulting in a reduction of neonatal morbidity with its associated short and long-term health care costs. Successful use of Eculizumab in this case suggests that complement inhibition may be an effective treatment strategy for severe preeclampsia/HELLP syndrome.

AB - Severe preeclampsia with hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome is a leading cause of maternal and neonatal morbidity and mortality worldwide. Occurrence at an extremely premature gestational age is most challenging as there are dichotomous imperatives: delivery as definitive therapy for maternal health vs. prolongation of pregnancy to avoid prematurity and associated morbidities. We describe a patient presenting with severe preeclampsia/HELLP syndrome at 26 weeks gestation that was treated with Eculizumab, a targeted inhibitor of complement protein C5, which resulted in marked clinical improvement and complete normalization of lab parameters. Pregnancy was prolonged 17 days, likely resulting in a reduction of neonatal morbidity with its associated short and long-term health care costs. Successful use of Eculizumab in this case suggests that complement inhibition may be an effective treatment strategy for severe preeclampsia/HELLP syndrome.

KW - C5

KW - Complement

KW - Eculizumab

KW - HELLP syndrome

KW - Preeclampsia

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84873288473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873288473&partnerID=8YFLogxK

U2 - 10.1016/j.placenta.2012.11.014

DO - 10.1016/j.placenta.2012.11.014

M3 - Article

C2 - 23228435

AN - SCOPUS:84873288473

VL - 34

SP - 201

EP - 203

JO - Placenta

JF - Placenta

SN - 0143-4004

IS - 2

ER -